SOS EB Kids , a nonprofit organization whose mission is to improve the quality of life of Brazilian children living with Epidermolysis Bullosa (EB), recently received a donation of Curefini Ointment from Tanner Pharma Group (“Tanner”) and REV Pharma Corp. (“REV”).

This award shines a light on the Tanner team’s commitment to supporting the patients, NGOs and healthcare organizations the company serves, as well as supporting, strengthening and advocating for one another.

Oneness Biotech and Tanner Pharma UK Limited (“Tanner Pharma”) announced the initiation of an early access program for Fespixon in Europe, the UK, Russia, Latin America, the Middle East and North Africa (MENA) where Fespixon is not commercially available.

MAP International, a nonprofit health organization whose mission is to provide medicines and health supplies to those in need around the world so that they might experience life to the fullest, recently received a generous donation from Tanner Pharma Group.

Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a global Named Patient Program for ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS).

Again Life Italia S.r.l. and TannerLAC UK Limited, a wholly owned subsidiary of Tanner Pharma Group and company leader in the Latin American market, announced today the signing of a business partnership agreement for Latin America.

Epimune GmbH announced today that it has entered into a license agreement with TannerLAC UK Limited ("TannerLAC"), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro diagnostic test in the Latin American region.

Wilson – a small child with a rare muscle condition called centronuclear myopathy – gets life-saving medical equipment and goes home to his family after spending almost 2 years at the hospital thanks to the support of two patient organizations in Europe and US and the financial assistance and guidance from Tanner Pharma Group.

Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries.

Elevar Therapeutics, Inc. ("Elevar") and Tanner Pharma Group ("Tanner") announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named patient basis in areas outside of the United States (U.S.) where Apealea is not commercially available.

Tanner Pharma Group has announced the signing of a distribution agreement with Tasman Pharma Inc. The agreement names Tanner as a distributor of Versacloz in areas outside of the United States where the product is not yet registered (excluding Australia, Ireland, and United Kingdom).

Tanner Pharma Group, Inc. announced they have partnered with Endo Pharmaceuticals, Inc. to initiate a multi-year Named Patient Program for XIAFLEX® an important nonsurgical treatment option for patients with Dupuytren’s contracture and Peyronie’s disease.

The Partnership for Quality Medical Donations (PQMD), is proud to announce the addition of Tanner Pharma Group to their membership. The Charlotte, N.C., based global pharmaceutical company becomes the 42nd member of PQMD.

Tanner Pharma Group has announced the signing of a distribution agreement with MannKind Corporation, a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

The Max Foundation, an international health organization dedicated to serving cancer patients, and Tanner Pharma Group are committed partners in bringing thousands of patients around the globe daily access to cancer treatment.

Tanner Pharma Group has announced the signing of a distribution agreement with Partner Therapeutics, Inc. (PTx). The agreement names Tanner Pharma Group as a distributor of Leukine® (sargramostim) in areas outside of the United States and Canada where the product is not yet registered.

The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model designed to effectively deliver humanitarian donations of oncology products to identified patients in need in low resource countries.

Tanner Pharma Group’s Managed Access Programs (MAP) division and Proveca have agreed to launch a Managed Access Program for an oral formulation of glycopyrronium (Sialanar®) outside Europe and the USA.

Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s "Max Global Experience: Uganda," an expedition to raise awareness and funds for increased cancer treatment access in Africa.

Tanner Pharmaceuticals, Inc. and BurnsAdler Pharmaceuticals have merged to form Tanner Pharma Group.